VHH antibody found that binds a folded DNA aptamer and senses antibiotic-linked shape
Researchers at Saitama University have identified a small single-domain antibody, called VHH6, that binds preferentially to a folded DNA aptamer which recognises the veterinary antibiotic oxytetracycline (OTC). Its binding behaviour is influenced by the aptamer's structure, which suggests that antibodies can be used to read the shape of single-stranded DNA. The work, led by Naoto Nemoto and Koji Matsuoka, appears in the journal Antibodies.
Reversing the usual aptamer question
A DNA aptamer is a short, single-stranded DNA molecule that folds into a defined three-dimensional shape and binds a chosen target, such as a protein or a small chemical compound. Aptamers are increasingly studied as alternatives to conventional antibodies in biosensing and diagnostics.
Most work has asked which DNA sequences can recognise a given target. The team instead asked whether a protein could recognise the aptamer itself. Antibodies against certain specialised DNA structures have been described before. Finding antibodies that distinguish the varied folded forms of single-stranded aptamers, however, has received little attention.
How the antibody was found
The researchers worked with VHH antibodies, the compact single-domain fragments derived from camelid antibodies. They used an OTC-binding aptamer as the model and examined how antibody binding changed with or without OTC present.
Three methods were combined:
- cDNA display to screen candidate antibodies;
- surface plasmon resonance to measure binding properties;
- AlphaFold3 to predict the molecular interactions involved.
This pipeline yielded VHH6, whose binding depended on the structural features of the aptamer. According to first author Nayab Khaliq, a doctoral candidate, the results suggest that both the fold of the aptamer and the presence of a bound molecule can influence how it interacts with an antibody.
Why it matters for sensing and engineering
The study extends antibody recognition from proteins to folded nucleic acid structures, and it offers a route to studying and engineering protein–nucleic acid interactions. It also hints at a detection format for small molecules, which are often hard to measure with standard antibody assays because they offer few sites for antibodies to grip.
In the concept described by the authors, an aptamer would first capture the small molecule. An antibody would then recognise structural features of the resulting aptamer–target complex, giving a sandwich-like readout. Applications the team envisages over a five-to-10-year horizon include food safety, environmental monitoring and biotechnology, with antibiotic residues in animal-derived foods named as one example.
Limitations and next steps
The work is an early proof of concept, and the source does not report a working detection assay or performance figures. The researchers state that further work is needed to design aptamers that change shape more markedly when they bind their target, and to improve antibody specificity and detection sensitivity. Reliable analytical performance also remains to be established.
For researchers in aptamer technology and antibody engineering, the study offers a combined experimental and computational template for finding binders that report on nucleic acid conformation. Nemoto describes the long-term aim as combining the strengths of aptamers and antibodies to create new molecular recognition technologies.
Source: Research team finds an antibody that recognizes DNA shape and responds to antibiotic-induced structural changes (Medical Xpress, 20 November 2026).
Image: AI-generated illustration.
Working on this topic? Find a journal for your research or join the discussion on Scholars Post.


